Incidence of adverse #cardiovascular events in type 2 #diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database

Increased incidence of hospitalization for heart failure (HHF) among patients with diabetes is increasingly being reported. We investigated the incidence of adverse cardiovascular events including HHF among patients with type 2 diabetes mellitus, and the potential clinical improvement with sodium–glucose cotransporter 2 inhibitors (SGLT2i) using a contemporary administrative claims database from a large governmental district of Japan. We included initiators of any oral glucose‐lowering drugs … Continue reading Incidence of adverse #cardiovascular events in type 2 #diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database

Rate This

Clinical Outcomes in Patients With Heart #Failure Hospitalized With #COVID-19

The purpose of this study was to evaluate in-hospital outcomes among patients with a history of heart failure (HF) hospitalized with coronavirus disease-2019 (COVID-19).. ..Among 1,212,153 patients with history of HF, 132,312 patients were hospitalized from April 1, 2020, to September 30, 2020. A total of 23,843 patients (18.0%) were hospitalized with acute HF, 8,383 patients (6.4%) were hospitalized with COVID-19, and 100,068 patients (75.6%) … Continue reading Clinical Outcomes in Patients With Heart #Failure Hospitalized With #COVID-19

Rate This

#Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial RESEARCH DESIGN AND METHODS The subgroup of 2,605 patients with heart failure and reduced … Continue reading #Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

Rate This

Association of #Sedentary Time and Incident Heart #Failure Hospitalization in Postmenopausal Women

Background: The 2018 US Physical Activity Guidelines recommend reducing sedentary behavior (SB) for cardiovascular health. SB’s role in heart failure (HF) is unclear. Methods: We studied 80 982 women in the Women’s Health Initiative Observational Study, aged 50 to 79 years, who were without known HF and reported ability to walk ≥1 block unassisted at baseline. Mean follow-up was 9 years for physician-adjudicated incident HF … Continue reading Association of #Sedentary Time and Incident Heart #Failure Hospitalization in Postmenopausal Women

Rate This

Predictors of Mortality in Patients with Chronic Heart #Failure: Is #Hyponatremia a Useful Clinical Biomarker?

Chronic heart failure (CHF) is a global health burden. Despite advances in treatment, there remain well-recognised morbidity and mortality. Risk stratification requires the identification and validation of biomarkers, old and new. Hyponatremia has re-emerged as a prognostic marker in CHF patients.. ..Mean age of patients was 60.61 ± 12.63 (SD) years; 65.1% were males, and type 2 diabetes mellitus (DM) was present in 71%. Baseline … Continue reading Predictors of Mortality in Patients with Chronic Heart #Failure: Is #Hyponatremia a Useful Clinical Biomarker?

Rate This

#Anaemia, iron status, and gender predict the outcome in patients with chronic heart #failure

Anaemia and iron deficiency (ID) are frequently found in patients with chronic heart failure (CHF) and associated with adverse outcome. However, it is unclear whether absolute [transferrin saturation (TSAT) <20%, ferritin <100 μg/L] or inflammation‐driven functional ID (TSAT <20%, ferritin >100 μg/L) with and without anaemia had similar or different consequences for such patients Within this retrospective cohort study, 2223 patients (1601 men and 622 … Continue reading #Anaemia, iron status, and gender predict the outcome in patients with chronic heart #failure

Rate This

#Hypocalcaemia predicts 12‐month re‐hospitalization in heart #failure

Potential pathophysiology of heart failure with preserved ejection fraction (HFpEF) has not been fully explored. The aim of the study was to reveal the association of serum calcium concentration at baseline with 12‐month clinical outcome in the disease.. ..Multivariate COX regression analysis revealed that baseline hypocalcaemia was associated with the increased risk of cardiac re‐hospitalization and death during the follow‐up period (HR: 2.10, 95% CI: … Continue reading #Hypocalcaemia predicts 12‐month re‐hospitalization in heart #failure

Rate This

Right Ventricular Global Longitudinal Strain and Outcomes in Heart Failure with Preserved Ejection Fraction

Right ventricular (RV) strain has emerged as an accurate tool for RV function assessment and is a powerful predictor of survival in patients with heart failure with reduced ejection fraction. However, its prognostic impact in patients with heart failure with preserved ejection fraction (HFpEF) remains unclear. The aim of this study was to compare the prognostic value of RV global longitudinal strain (RVGLS) by two-dimensional … Continue reading Right Ventricular Global Longitudinal Strain and Outcomes in Heart Failure with Preserved Ejection Fraction

Rate This

FDA approves new treatment for a type of heart failure

Today, the U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. Heart failure occurs when the heart does not pump enough blood to support the body’s needs, and this type of heart failure happens when the heart’s main pumping chamber, the left ventricle, … Continue reading FDA approves new treatment for a type of heart failure

Rate This

Updating insights into #rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses

individual patient level data (IPD) ..The odds ratios for myocardial infarction, heart failure, cardiovascular related death, and non-cardiovascular related death were 1.17 (0.92 to 1.51), 1.54 (1.14 to 2.09), 1.15 (0.55 to 2.41), and 1.18 (0.60 to 2.30), respectively. For analyses including trials for which IPD were not available, odds ratios for myocardial infarction and cardiovascular related death were attenuated (1.09, 0.88 to 1.35, and … Continue reading Updating insights into #rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses

Rate This

Updating insights into #rosiglitazone and #cardiovascular risk through shared data: individual patient and summary level meta-analyses

..The odds ratios for myocardial infarction, heart failure, cardiovascular related death, and non-cardiovascular related death were 1.17 (0.92 to 1.51), 1.54 (1.14 to 2.09), 1.15 (0.55 to 2.41), and 1.18 (0.60 to 2.30), respectively. For analyses including trials for which IPD were not available, odds ratios for myocardial infarction and cardiovascular related death were attenuated (1.09, 0.88 to 1.35, and 1.12, 0.72 to 1.74, respectively). … Continue reading Updating insights into #rosiglitazone and #cardiovascular risk through shared data: individual patient and summary level meta-analyses

Rate This